Paratek Starts Final Stage Study Of Oral-only Omadacycline In ABSSSI By: Benzinga via Benzinga August 15, 2016 at 09:24 AM EDT Paratek Pharmaceuticals Inc (NASDAQ: PRTK) commenced final stage study of oral-only Omadacycline by dosing the first patient with ... Read More >> Related Stocks: Paratek Pharma Inc